Compare Cassava Sciences Inc (FLNA) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $57.02. The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SPUS | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $59.51 |
52-Week Low | $1.09 | $45.17 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
SPUS trades at $56.97, down 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights the strength of U.S. dividend strategies, with SPUS paying consistent dividends. Institutional interest is growing, as evidenced by Farther Finance Advisors increasing its stake in Q4 2025.
The outlook for SPUS is supported by dividend stability and institutional accumulation, but key valuation ratios are unavailable, limiting fundamental assessment. Risks include market volatility and reliance on dividend strategy performance. The stock's technical strength suggests potential upside if momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
